Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME LANDMAN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1346204690
CMS profile
105508
Location
AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$185.24

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $165.93 3
Education $19.31 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Genentech, Inc. $139.49 1
BioCryst US Sales Co., LLC $21.16 1
Novartis Pharmaceuticals Corporation $19.31 1
Organon LLC $5.28 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME LANDMAN

NPI 1346204690 · CMS profile ID 105508

Allopathic & Osteopathic Physicians / Allergy & Immunology

AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346204690?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346204690?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346204690?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1346204690?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $185.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BioCryst US Sales Co., LLC $21.1612/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222006853 CMS
Genentech, Inc. $139.4909/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211519823 CMS
Novartis Pharmaceuticals Corporation $19.3103/19/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1200598757 CMS
Organon LLC $5.2802/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237696472 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $290.90 12
PY2020 $140.24 7
PY2021 $151.53 7
PY2022 $161.81 7
PY2023 $108.04 5
PY2025 $185.24 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $751,515.35 131
PY2024 Principal investigator $525,143.48 126
PY2023 Principal investigator $497,961.58 102
PY2022 Principal investigator $447,451.34 86
PY2021 Principal investigator $586,667.15 102
PY2020 Recipient $11,702.26 1
PY2020 Principal investigator $473,131.41 28
PY2019 Recipient $1,525.00 1
PY2019 Principal investigator $615,806.88 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

131 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $2,605.20 12/15/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138551
Principal investigator 1 GlaxoSmithKline, LLC. $275.74 12/11/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192120418
Principal investigator 1 GlaxoSmithKline, LLC. $1,838.03 12/11/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192175190
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,002.22 12/11/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048084
Principal investigator 1 GENZYME CORPORATION $5,467.00 12/08/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138543
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 12/05/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192113573
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 12/05/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192174195
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $346.95 12/04/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048086
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,494.54 12/04/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048088
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $346.95 12/04/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048236
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $346.95 12/04/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048238
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $346.95 12/04/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048240
Principal investigator 1 GlaxoSmithKline, LLC. $705.00 11/24/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192174186
Principal investigator 1 GlaxoSmithKline, LLC. $43,624.35 11/21/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192120490
Principal investigator 1 GlaxoSmithKline, LLC. $4,730.00 11/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113566
Principal investigator 1 GlaxoSmithKline, LLC. $216.00 11/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192120461
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,751.85 11/20/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048090
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/19/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113780
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 11/19/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048250
Principal investigator 1 GENZYME CORPORATION $238.16 11/17/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138540
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $346.95 11/13/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048092
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,498.18 11/13/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048094
Principal investigator 1 GlaxoSmithKline, LLC. $2,724.00 11/12/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113815
Principal investigator 1 GlaxoSmithKline, LLC. $216.00 11/12/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192120437
Principal investigator 1 GlaxoSmithKline, LLC. $2,030.00 11/12/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192174178
Principal investigator 1 GlaxoSmithKline, LLC. $1,288.00 11/12/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192174199
Principal investigator 1 GlaxoSmithKline, LLC. $356.00 10/28/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113786
Principal investigator 1 GENZYME CORPORATION $1,950.00 10/27/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138538
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $184.63 10/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048096
Principal investigator 1 GlaxoSmithKline, LLC. $1,521.61 10/23/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192112595
Principal investigator 1 GlaxoSmithKline, LLC. $22,146.30 10/23/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113803
Principal investigator 1 GlaxoSmithKline, LLC. $2,021.62 10/23/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192120472
Principal investigator 1 GENZYME CORPORATION $3,169.20 10/20/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138535
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,039.30 10/14/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048098
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,498.18 10/09/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048100
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 10/09/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048248
Principal investigator 1 GENZYME CORPORATION $595.00 10/06/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138526
Principal investigator 1 GENZYME CORPORATION $1,800.00 10/06/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138530
Principal investigator 1 GlaxoSmithKline, LLC. $5,257.80 10/02/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192113791
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,332.55 09/25/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048102
Principal investigator 1 GlaxoSmithKline, LLC. $21,523.59 09/24/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113601
Principal investigator 1 GENZYME CORPORATION $5,374.56 09/22/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138523
Principal investigator 1 GlaxoSmithKline, LLC. $5,821.14 09/12/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192112571
Principal investigator 1 GlaxoSmithKline, LLC. $3,012.00 09/10/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192174192
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $364.95 09/04/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048104
Principal investigator 1 GENZYME CORPORATION $375.00 09/03/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138498
Principal investigator 1 GENZYME CORPORATION $2,960.48 09/03/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138505
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,498.18 08/27/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048106
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 08/27/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048108
Principal investigator 1 GENZYME CORPORATION $418.38 08/25/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138494
Principal investigator 1 GENZYME CORPORATION $4,506.72 08/25/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138510
Principal investigator 1 GENZYME CORPORATION $1,155.00 08/25/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138514
Principal investigator 1 GlaxoSmithKline, LLC. $18,843.66 08/22/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192120455
Principal investigator 1 GlaxoSmithKline, LLC. $5,605.53 08/21/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192175186
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,522.53 08/19/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048110
Principal investigator 1 GlaxoSmithKline, LLC. $3,251.71 08/15/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192168603
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,996.36 08/13/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048112
Principal investigator 1 GlaxoSmithKline, LLC. $1,765.00 08/07/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192120484
Principal investigator 1 GlaxoSmithKline, LLC. $2,030.00 08/07/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192174208
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $364.95 08/06/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048114
Principal investigator 1 GENZYME CORPORATION $2,557.76 08/04/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138487
Principal investigator 1 GlaxoSmithKline, LLC. $312.00 08/01/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192120508
Principal investigator 1 GlaxoSmithKline, LLC. $790.00 07/25/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192120467
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $364.95 07/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048116
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,498.18 07/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048118
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,926.17 07/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048120
Principal investigator 1 GlaxoSmithKline, LLC. $11,921.00 07/18/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113774
Principal investigator 1 GlaxoSmithKline, LLC. $6,923.09 07/16/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192168599
Principal investigator 1 Novartis Pharmaceuticals Corporation $92,560.02 07/15/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307789
Principal investigator 1 GENZYME CORPORATION $2,584.00 07/02/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138477
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 07/02/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113798
Principal investigator 1 GlaxoSmithKline, LLC. $18,774.52 06/25/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192112577
Principal investigator 1 GlaxoSmithKline, LLC. $10,800.00 06/25/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192120449
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,606.06 06/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048122
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $600.00 06/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048124
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $364.95 06/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048126
Principal investigator 1 GlaxoSmithKline, LLC. $10,759.32 06/23/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192113579
Principal investigator 1 GENZYME CORPORATION $1,300.00 06/16/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138475
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 06/05/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048128
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $216.00 06/05/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048130
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $364.95 06/05/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048132
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 06/04/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192120478
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 06/03/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192112583
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 05/30/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192112609
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $364.95 05/28/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048134
Principal investigator 1 GENZYME CORPORATION $7,620.88 05/27/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138472
Principal investigator 1 GlaxoSmithKline, LLC. $1,010.81 05/22/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192168617
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,236.10 05/22/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048136
Principal investigator 1 GlaxoSmithKline, LLC. $13,149.18 05/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192112616
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $364.95 05/15/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048138
Principal investigator 1 GENZYME CORPORATION $6,939.60 05/12/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138469
Principal investigator 1 GENZYME CORPORATION $1,300.00 05/05/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138456
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,500.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185537349
Principal investigator 1 GENZYME CORPORATION $1,415.00 04/28/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138461
Principal investigator 1 GlaxoSmithKline, LLC. $3,467.55 04/28/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192112589
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 04/28/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192112603
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,026.90 04/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048140
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.85 04/17/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048142
Principal investigator 1 GlaxoSmithKline, LLC. $5,557.85 04/09/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192168590
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $625.00 04/04/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048144
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 04/02/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192120430
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 04/02/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192174203
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 03/25/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048246
Principal investigator 1 GENZYME CORPORATION $6,700.96 03/24/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138438
Principal investigator 1 GlaxoSmithKline, LLC. $790.00 03/24/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192120502
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 03/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192120424
Principal investigator 1 GlaxoSmithKline, LLC. $9,608.95 03/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192120443
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 03/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192174182
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.85 03/13/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048146
Principal investigator 1 GENZYME CORPORATION $4,510.96 03/10/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138436
Principal investigator 1 GlaxoSmithKline, LLC. $3,467.55 03/07/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192113560
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 03/06/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192168608
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $405.00 03/06/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048148
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,688.64 02/27/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048150
Principal investigator 1 GlaxoSmithKline, LLC. $184.55 02/26/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192168613
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048244
Principal investigator 1 GENZYME CORPORATION $9,792.56 02/18/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138443
Principal investigator 1 GENZYME CORPORATION $6,038.80 02/18/2025 Non-covered Recipient Entity
Florida Center For Allergy Asthma Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138448
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 02/13/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048152
Principal investigator 1 GlaxoSmithKline, LLC. $790.00 02/12/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192113608
Principal investigator 1 GlaxoSmithKline, LLC. $2,016.00 02/07/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192113588
Principal investigator 1 GlaxoSmithKline, LLC. $754.00 02/07/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192113595
Principal investigator 1 GlaxoSmithKline, LLC. $2,277.45 01/30/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192120496
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,120.91 01/30/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048400
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,205.55 01/30/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048402
Principal investigator 1 GlaxoSmithKline, LLC. $992.70 01/13/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192113809
Principal investigator 1 GlaxoSmithKline, LLC. $1,521.61 01/09/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192168594
Principal investigator 1 Novartis Pharmaceuticals Corporation $53,141.29 01/09/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190307783
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 01/08/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048242
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,046.95 01/03/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185537347
Principal investigator 1 Novartis Pharmaceuticals Corporation $85,042.73 01/01/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190307791